AzTrials
AzTrials

Atopic DermatitisPhase 3BREEZE-AD-PEDSNCT03952559

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

A Phase 3 study testing Baricitinib and Topical corticosteroid in people with Atopic Dermatitis, run by Eli Lilly and Company at 78 sites in 17 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis. Read more about this study

Who is it for?
Ages 2 to 17 years
Conditions the study is for
Atopic Dermatitis
What is being tested?
Baricitinib and Topical corticosteroid
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
516 participants
Where
78 sitesin 17 countries
Study dates
24 May 2019to 22 May 2026
Phase
Phase 3

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • At or above the 5th percentile of weight for age.
  • Have been diagnosed with moderate to severe atopic dermatitis for at least 12 months (if 6 years old or older) or at least 6 months (if 2 up to 6 years old).
  • Have had inadequate response or intolerance to existing topical (applied to the skin) medications within 6 months preceding screening.
  • Are willing to discontinue certain treatments for eczema (such as systemic and topical treatments during a washout period).
  • Agree to use emollients daily.

Who cannot join

  • Are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus), or a history of erythrodermic, refractory, or unstable skin disease that requires frequent hospitalizations and/or intravenous treatment for skin infections.
  • A history of eczema herpeticum within 12 months, and/or a history of 2 or more episode of eczema herpeticum in the past.
  • Participants who are currently experiencing a skin infection that requires treatment, or is currently being treated, with topical or systemic antibiotics.
  • Have any serious illness that is anticipated to require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma).
  • Have been treated with the following therapies:
  • Monoclonal antibody for less than 5 half-lives prior to beginning study treatment.
Show all 18Show fewer
  • Received prior treatment with any oral Janus kinase (JAK) inhibitor.
  • Received any parenteral corticosteroids administered by intramuscular or intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior to planned initiation of study drug or are anticipated to require parenteral injection of corticosteroids during the study.
  • Have had an intra-articular corticosteroid injection within 2 weeks prior to study entry or within 6 weeks prior to planned initiation of study drug.
  • Have high blood pressure characterized by a repeated systolic or diastolic blood pressure >95th percentile based on age, sex and height.
  • Have had major surgery within the past eight weeks or are planning major surgery during the study.
  • Have experienced any of the following within 12 weeks of screening: venous thromboembolic event (VTE), myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage III/IV heart failure.
  • Have a history of VTE or are considered at high risk of VTE as deemed by the investigator.
  • Have a history or presence of cardiovascular, respiratory, hepatic, chronic liver disease gastrointestinal, endocrine, hematological, neurological, lymphoproliferative disease or neuropsychiatric disorders or any other serious and/or unstable illness.
  • Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection including herpes zoster (shingles or chicken pox), tuberculosis.
  • Have specific laboratory abnormalities.
  • Have received certain treatments that are contraindicated.
  • Pregnant or breastfeeding.

Trial locations and contacts

78 sites in 17 countries.

78 sites in 17 countries

Japan10 sites
  • Matsuda Tomoko Dermatological Clinic

    Fukuoka, 819-0167

  • Fukuyama City Hospital

    Fukuyama, Hiroshima, 721-8511

  • Nagoya Medical Center

    Nagoya, Aichi-ken, 460-0001

  • National Hospital Organization Sagamihara National Hospital

    Sagamihara, Kanagawa, 252-0392

  • Kume Clinic

    Sakai, Osaka, 593-8324

  • Takeda Dermatology Skincare Clinic

    Sapporo, Hokkaido, 004-0063

  • Dokkyo Medical University Hospital

    Shimotsuga, Tochigi, 321-0293

  • Shinjuku Minamiguchi Hifuka

    Tokyo, 160-0023

  • Senri-Chuo Hanafusa Dermatology Clinic

    Toyonaka, Osaka, 560-0085

  • National Mie Hospital

    Tsu, Mie-ken, 514-0125

Other trials in Japan

France7 sites
  • Centre Hospitalier Régional Universitaire de Brest - Hôpital Morvan

    Brest, Finistère, 29200

  • Hôpital Saint Vincent de Paul

    Lille, Hauts-de-France, 59020

  • Chu Saint Eloi

    Montpellier, Languedoc-Roussillon, 34295

  • Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu

    Nantes, Loire-Atlantique, 44093

  • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet

    Nice, Alpes-Maritimes, 6200

  • Hôpitaux Drôme Nord - Romans

    Romans-sur-Isère, Drôme, 26102

  • CHU de Toulouse - Hopital Larrey

    Toulouse, Midi-Pyrénées, 31400

Other trials in France

Spain7 sites
  • Hospital Sant Joan de Déu

    Esplugues de Llobregat, Barcelona [Barcelona], 8950

  • Hospital Infantil Universitario Niño Jesús

    Madrid, 28009

  • Hospital Universitario La Paz

    Madrid, 28046

  • Hospital Universitario Puerta de Hierro Majadahonda

    Majadahonda, Madrid, Comunidad de, 28222

  • Clinica Universidad de Navarra

    Pamplona, Navarre, 31008

  • CHOP-Centro De Especialidades De Mollabao

    Pontevedra, Pontevedra [Pontevedra], 36001

  • Hospital Universitario Quironsalud Madrid

    Pozuelo de Alarcón, Madrid, 28223

Other trials in Spain

Taiwan6 sites
  • Chang Gung Memorial Hospital at Kaohsiung

    Kaohsiung Niao Sung Dist, Kaohsiung, 83301

  • Chung Shan Medical University Hospital

    Taichung, 402

  • National Taiwan University Hospital

    Taipei, 10002

  • Taipei Veterans General Hospital

    Taipei, 11217

  • Chang Gung Medical Foundation-Linkou Branch

    Taoyuan, 333

  • Chang Gung Memorial Hospital - Linkou Branch

    Taoyuan, 333

Other trials in Taiwan

Brazil5 sites
  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, 90035-903

  • IBPClin - Instituto Brasil de Pesquisa Clínica

    Rio de Janeiro, 22241-180

  • IDERJ - Instituto de Dermatologia e Estética do Brasil

    Rio de Janeiro, 22470-220

  • Faculdade de Medicina do ABC

    Santo André, São Paulo, 09060-870

  • Hospital do Servidor Público Estadual - IAMSPE - centro de estudos urológicos

    São Paulo, 04039-901

Other trials in Brazil

Czechia5 sites
  • Fakultni nemocnice Hradec Kralove

    Hradec Králové, Hradec Králové, 500 05

  • Nemocnice AGEL Novy Jicin a.s.

    Nový Jičín, Nový Jičín, 741 01

  • Fakultni Nemocnice v Motol

    Prague, Praha 5, 150 06

  • Fakultni nemocnice Bulovka

    Prague, Praha 8, 180 81

  • Sanatorium profesora Arenbergera

    Prague, 128 00

Other trials in Czechia

Mexico5 sites
  • Instituto de Investigaciones Aplicadas a la Neurociencia A.C.

    Durango, 34000

  • Centro de Atención en Enfermedades Inflamatorias CATEI

    Guadalajara, Jalisco, 44638

  • Centro Regiomontano de Investigación

    Monterrey, Nuevo León, 64060

  • Hospital Universitario Dr. Jose Eleuterio Gonzalez

    Monterrey, Nuevo León, 66460

  • Arké SMO S.A de C.V

    Veracruz, 91900

Other trials in Mexico

Argentina4 sites
  • Fundacion CIDEA

    Buenos Aires, Ciudad Autonoma Buenos Aires, C1121ABE

  • Fundación Respirar

    Buenos Aires, C1426ABP

  • Instituto de Neumonología Y Dermatología

    Capital Federal, Buenos Aires, 1425

  • Centro de Investigaciones Metabólicas (CINME)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, 1027

Other trials in Argentina

Germany4 sites
  • Universitaetsklinikum Carl Gustav Carus Dresden

    Dresden, Saxony, 01307

  • Universitätsklinikum Frankfurt

    Frankfurt am Main, Hesse, 60590

  • Katholisches Kinderkrankenhaus Wilhelmstift

    Hamburg, 22149

  • Universitätsklinikum Münster

    Münster, North Rhine-Westphalia, 48149

Other trials in Germany

Israel4 sites
  • Emek Medical Center

    Afula, Northern District, 1834111

  • Soroka Medical Center

    Beersheba, Southern District, 8410101

  • Sheba Medical Center

    Ramat Gan, Central District, 5262100

  • Sourasky Medical Center

    Tel Aviv, Tell Abīb, 6423906

Other trials in Israel

Russia4 sites
  • Krasnodar Clinical Skin and Venereal Diseases Dispensary

    Krasnodar, Krasnodarskiy Kray, 354057

  • Children's Health Research Center of RAMS

    Moscow, Moscow, 115478

  • Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology - Central branch

    Moscow, Moscow, 127473

  • Tula Regional Clinical Dermatovenerological Dispensary

    Tula, Tula Oblast, 300053

Other trials in Russia

Australia3 sites
  • Royal Children's Hospital

    Melbourne, Victoria, 3052

  • The Children's Hospital at Westmead

    Westmead, New South Wales, 2145

  • Veracity Clinical Research

    Woolloongabba, Queensland, 4102

Other trials in Australia

Austria3 sites
  • Medizinische Universität Graz

    Graz, Styria, 8036

  • Medizinische Universität Wien

    Vienna, State of Vienna, 1090

  • Sozialmedizinisches Zentrum Ost/Donauspital

    Vienna, State of Vienna, 1220

Other trials in Austria

India3 sites
  • B. J. Medical College & Civil Hospital

    Ahmedabad, Gujarat, 380016

  • Aakash Healthcare: Super Speciality Hospital -Dwarka

    Dwarka, National Capital Territory of Delhi, 110075

  • Sir Ganga Ram Hospital

    New Delhi, National Capital Territory of Delhi, 110060

Other trials in India

Poland3 sites
  • Centrum Badan Klinicznych PI-House sp. z o.o.

    Gdansk, Pomeranian Voivodeship, 80-546

  • Diamond Clinic

    Krakow, Lesser Poland Voivodeship, 31-559

  • Specjalistyczne Gabinety Lekarskie "DERMED" Anna Kaszuba

    Lodz, Łódź Voivodeship, 90-265

Other trials in Poland

United Kingdom3 sites
  • Royal Hospital for Sick Children

    Glasgow, Glasgow City, G514TF

  • St Thomas's Hospital

    London, London, City of, SE1 7EH

  • Queen's Medical Centre, Nottingham University Hospitals

    Nottingham, Nottinghamshire, NG7 2UH

Other trials in United Kingdom

Hungary2 sites
  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ

    Szeged, Csongrád megye, 6720

  • Allergo-Derm Bakos Kft

    Szolnok, Jász-Nagykun-Szolnok, 5000

Other trials in Hungary

About this study

Official title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis

The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.

Being tested
Baricitinib, Placebo, Topical corticosteroid
Keywords
eczema, atopic eczema
Medical subject headings
Dermatitis, Atopic, Eczema

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BaricitinibDrug

    Also called LY3009104

    Administered orally

  • PlaceboDrug

    Administered orally

  • Topical corticosteroidDrug

    Administered as standard-of-care

Study groups in NCT03952559
Study groupRoleWhat they receive
Baricitinib Open Label High Dose (PK Lead-in)ExperimentalParticipants 10 to < 18 years received Baricitinib high dose (4 mg) administered orally in tablet form QD. Participants 2 to < 10 years received Baricitinib high dose (2 mg) administered as oral suspension (1 mL) QD.
Receives: Drug: Baricitinib; Drug: Topical corticosteroid
Baricitinib High DoseExperimentalParticipants 10 to < 18 years received Baricitinib high dose (4 mg) and placebo to maintain the blind, administered orally in tablet form QD. Participants 2 to < 10 years received Baricitinib high dose (2 mg) administered as oral suspension QD or placebo oral suspension QD to maintain the blind.
Receives: Drug: Baricitinib; Drug: Topical corticosteroid
Baricitinib Medium DoseExperimentalParticipants 10 to < 18 years received Baricitinib low dose (1 mg) and placebo to maintain the blind, administered orally in tablet form QD. Participants 2 to < 10 years received Baricitinib low dose (0.5 mg) administered as oral suspension QD or placebo oral suspension QD to maintain the blind.
Receives: Drug: Baricitinib; Drug: Topical corticosteroid
Baricitinib Low DoseExperimentalParticipants 10 to < 18 years received Baricitinib low dose (1 mg) and placebo to maintain the blind, administered orally in tablet form QD. Participants 2 to < 10 years received Baricitinib low dose (0.5 mg) administered as oral suspension QD or placebo oral suspension QD to maintain the blind.
Receives: Drug: Baricitinib; Drug: Topical corticosteroid
PlaceboPlacebo comparatorParticipants 10 to < 18 years received placebo tablets. Participants 2 to < 10 years received placebo as oral suspension.
Receives: Drug: Placebo; Drug: Topical corticosteroid

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥2 Point Improvement

    Percentage of participants achieving IGA of 0 or 1 with a ≥2 point improvement is presented. The IGA measures the investigator's global assessment of the participant's overall severity of their Atopic Dermatitis, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

    Measured: Week 16

  2. Open Label Population Pharmacokinetics (Pop PK): Maximum Observed Drug Concentration at Steady State (Cmax,ss) of LY3009104

    Open label Pop PK: Cmax,ss was derived by a population pharmacokinetics approach.

    Measured: Predose; 0.25 hours (h); 0.5 h; 1 h; 2-4 h; 4 h and 4-6 h post dose

  3. Open Label Pop PK: Area Under the Concentration-Time Curve for Dosing Interval at Steady State (AUCtau,ss) of LY3009104

    Open label Pop PK: AUCtau,ss was derived by a population pharmacokinetics approach.

    Measured: Predose; 0.25 h; 0.5 h; 1 h; 2-4 h; 4 h and 4-6 h post dose

Secondary outcomes (31)
  1. Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75)

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

    The results were analyzed using non-responder imputation (NRI). All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as EASI75.

    Measured: Week 16

  2. Percentage of Participants Achieving EASI90

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI90 is defined as a ≥ 90% improvement from baseline in the EASI score.

    The results were analyzed using non-responder imputation (NRI). All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as EASI90.

    Measured: Week 16

  3. Change From Baseline in EASI Score

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs (1) erythema (2)edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2 and 3. The final EASI score is obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe).

    Least Square (LS) Means were calculated using a mixed model repeated measures (MMRM) model with treatment, age cohort, region, baseline disease severity (IGA), visit, treatment-by-age cohort interaction and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Measured: Baseline, Week 16

  4. Percentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)

    The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with visual analog scale (VAS) where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. The SCORAD75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the SCORAD score.

    Measured: Week 16

  5. Percentage of Participants Achieving a 4-Point Improvement in Itch Numeric Rating Scale (NRS) for Participants 10 to <18 Years Old at Study Entry

    The Itch Numeric Rating Scale (NRS) is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participants itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.

    Measured: Week 16

  6. Percentage of Participants Achieving EASI50

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI50 is defined as a ≥ 50% improvement from baseline in EASI score.

    Measured: Week 16

  7. Percentage of Participants Achieving IGA of 0

    The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

    Measured: Week 16

  8. Change From Baseline in SCORAD

    The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease.

    LS Means were calculated using a MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Measured: Baseline, Week 16

  9. Percentage of Participants Achieving SCORAD90

    The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. SCORAD90 is defined as a ≥ 90% improvement from baseline in the SCORAD score.

    Measured: Week 16

  10. Change From Baseline in Body Surface Area (BSA) Affected

    Body surface area affected by atopic dermatitis will be assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. Overall percent BSA of all 4 body regions ranges from 0% to 100 % with higher values representing greater severity of atopic dermatitis. LS Means calculated using MMRM model with treatment, age cohort, region, baseline disease severity (IGA), visit, treatment-by-age cohort interaction and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Measured: Baseline, Week 16

  11. Percentage of Participants Developing Skin Infections Requiring Antibiotic Treatment

    Percentage of participants developing skin infections requiring antibiotic treatment

    Measured: Week 16

  12. Mean Number of Days Without Use of Background Topical Corticosteroid (TCS)

    Mean number of days without use of background TCS was presented. The ANOVA model includes treatment, age cohort, region, and baseline disease severity (IGA) as factors.

    Measured: Baseline Through 16 Weeks

  13. Mean Gram Quantity of TCS Use (Tube Weights)

    The dispensed TCS tubes were weighed with cap (without the carton) to determine the dispensed amount of TCS in grams. Returned tubes were weighed with cap (without the carton) to determine the amount of TCS in grams used at each visit. Analysis was done via analysis of variance (ANOVA), with geographic region, baseline disease severity, and treatment as factors in the model.

    Measured: Baseline through 16 Weeks

  14. Change From Baseline in Itch NRS for Participants 10 to <18 Years at Study Entry

    The Itch NRS is a participant-administered, 11-point horizontal scale, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.

    LS Means were calculated using mixed model repeated measures (MMRM) model includes treatment, age cohort, region, baseline disease severity (IGA), visit, treatment-by-age cohort interaction and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Measured: Baseline, Week 16

  15. Change From Baseline in the Parent-Reported Itch Severity Measure (PRISM) for Participants 2 to <10 Years at Study Entry

    The Parent-Reported Itch Severity Measure (PRISM) is a single-item, parent/caregiver administered scale that reports the overall severity of their child's itching. Parent/Caregiver's report the overall severity of their child's itching based on observed actions of the child in the past 24 hours. Response options range include "No Itch," "Mild," "Moderate," "Severe," and "Very Severe." The PRISM will be completed for participants <10 years old by the parent/caregiver.

    LS Means were calculated using mixed model repeated measures (MMRM) model includes treatment, age cohort, region, baseline disease severity (IGA), visit, treatment-by-age cohort interaction and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Measured: Baseline, Week 16

  16. Change From Baseline on the Patient-Oriented Eczema Measure (POEM) Total Score

    The POEM is a simple, 7-item, patient-administered scale that assesses disease severity in children and adults. Participants respond to questions about the frequency of 7 symptoms (itching, sleep disturbance, bleeding, weeping/oozing, cracking, flaking, and dryness/roughness) over the last week on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). Scores range from 0-28 with higher total scores indicating greater disease severity.

    LS Means were calculated using MMRM model includes treatment, age cohort, region, baseline disease severity (IGA), visit, treatment-by-age cohort interaction and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Measured: Baseline, Week 16

  17. Change From Baseline in Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD) Score for Participants 10 to <18 Years at Study Entry

    The PGI-S-AD is a single-item question asked to the participants on how they would rate their overall atopic dermatitis symptoms over the past 24 hours to evaluate the severity of the disease at that point in time. The 5 categories of responses range from "(0) no symptoms", "(1) very mild", "(2) mild" "(3) moderate", and "(4) severe".

    LS Means were calculated using mixed model repeated measures (MMRM) model includes treatment, age cohort, region, baseline disease severity (IGA), visit, treatment-by-age cohort interaction and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Measured: Baseline, Week 16

  18. Change From Baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) - Pediatric Depression for Participants 5 to <18 Years at Study Entry

    PROMIS is a set of person-centered measures that evaluates and monitors physical, mental and social health in adults and children. The PROMIS Depression item bank assesses self-reported negative mood (sadness, guilt), views on self (self-criticism, worthlessness), social cognition (loneliness, interpersonal alienation), decreased positive affect and engagement (loss of interest, meaning, and purpose). The PROMIS Depression Short Form (8a v2.0 and 6a v2.0) is available in pediatric self-report (ages 8 to <18 years) and for parents/caregivers serving as proxy reporters for children (ages 5 to <8 years). Children aged <5 years will not complete assessment. Both pediatric self-report and proxy-report versions assess depression "in past seven days." Response options range from 1 = Never;2 = Rarely;3 = Sometimes;4 = Often; to 5 = Almost always. Total raw scores were converted to T-Scores (mean= 50 and a standard deviation = 10) with higher scores representing greater depression.

    Measured: Baseline, Week 16

  19. Change From Baseline in the PROMIS-Pediatric Anxiety for Participants 5 to <18 Years at Study Entry

    PROMIS is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. The PROMIS Anxiety item bank assesses self-reported fear (fearfulness, panic), anxious misery (worry, dread), hyperarousal (tension, nervousness, restlessness), and somatic symptoms related to arousal (racing heart, dizziness). The PROMIS Anxiety Short Form (8 questions, 8a v2.0) is available in a pediatric self-report (ages 8 to <18 years) and for parents/caregivers serving as proxy reporters for their children (youth ages 5 to <8 years old). Children aged <5 years will not complete this assessment. Both pediatric self-report and proxy-report versions assess anxiety "in the past seven days." Response options range from 1= Never; 2 = Rarely; 3 = Sometimes; 4 = Often; to 5 = Almost always. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater anxiety.

    Measured: Baseline, Week 16

  20. Change From Baseline in the Children's Dermatology Life Quality Index (CDLQI) at Week 16 for Participants 4 to <18 Years at Study Entry

    CDLQI is a validated 10 question tool to measure impact of skin disease on QOL in children by assessing how much the skin problem has affected the subjects over past week. Nine questions were scored as follows: Very much = 3, Quite a lot = 2, Only a little = 1, Not at all or unanswered = 0. Question 7 has an added possible response, which was scored as 3. CDLQI equals the sum of the score of each question (max. = 30, min. = 0). Higher the score, the greater the impact on QOL. A negative change from baseline indicated improvement. LS Means were calculated using mixed model repeated measures (MMRM) model includes treatment, age cohort, region, baseline disease severity (IGA), visit, treatment-by-age cohort interaction and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Measured: Baseline, Week 16

  21. Change From Baseline in Infants' Dermatology Quality of Life Index (IDQOL) at Week 16 for Participants 2 to <4 Years at Study Entry

    Infants' Dermatitis Quality of Life Index (IDQOL) is used to evaluate quality of life for subjects of age less than 4 years. IDQOL questionnaires were designed for infants (below the age of 4 years) with atopic dermatitis. The IDQOL was calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score in each questionnaire, the more quality of life is impaired. A negative change from baseline indicated improvement. LS Means were calculated using mixed model repeated measures (MMRM) model includes treatment, age cohort, region, baseline disease severity (IGA), visit, treatment-by-age cohort interaction and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Measured: Week 16

  22. Change From Baseline on the Work Productivity and Activity Impairment: Atopic Dermatitis - Caregiver (WPAI-AD-CG) Score

    The Atopic Dermatitis Caregiver (WPAI-AD-CG) assesses the effect of a child's atopic dermatitis on the parent/caregiver's work productivity during the past 7 days. The WPAI-AD consists of 6 items grouped in 4 domains: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment, that range from 0% to 100%, Scores are calculated as impairment percentages with higher scores indicating greater impairment and less productivity.

    LS Mean were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Measured: Baseline, Week 16

  23. Change From Baseline on the European Quality of Life-5 Dimensions-Youth (EQ-5D-Y) for Participants 4 to <18 Years at Study Entry

    The EQ-5D-Y questionnaire is health status related and self-completed for pediatric participants ≥8 years old and completed by parents/caregivers for children 4 to <8 years old. Health state profile assessed health in 5 dimensions (Mobility,selfcare,usual activities,pain/discomfort, anxiety/depression) to obtain index score, each with three levels of response (no problems,some problems,a lot of problems). Participants indicated their health state by choosing appropriate level from each dimension. Visual analog scale on which participant rates their perceived health state from 0 ("worst health you can imagine") to 100 ("best health you can imagine") is presented.Higher the score the better the health status. LS Means uses MMRM model which includes treatment,age cohort,region,baseline disease severity(IGA),visit,treatment-by-age cohort interaction and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Measured: Baseline, Week 16

  24. Change From Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS) for Participants 10 to <18 Years at Study Entry

    Atopic Dermatitis Sleep Scale (ADSS) is a 3-item, participant-administered questionnaire developed to assess the impact of itch on sleep including difficulty falling asleep, frequency of waking, and difficulty getting back to sleep last night. Item 2, frequency of waking last night is reported by selecting the number of times they woke up each night, ranging from 0 to 29 times, where the higher a number indicates a worse outcome. The ADSS is designed to be completed daily, using a daily diary, with respondents thinking about sleep "last night." Each item is scored individually.

    LS Means were calculated using a MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by- visit-interaction as fixed continuous effects.

    Measured: Baseline, Week 16

  25. Change From Baseline in Skin Pain NRS for Participants 10 to <18 Years at Study Entry

    Skin Pain NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no pain" and 10 representing "worst pain imaginable." Overall severity of a participant's skin pain is indicated by selecting the number, using a daily diary, that best describes the worst level of skin pain in the past 24 hours.

    LS Means were calculated using a MMRM model with treatment, age cohort, region, baseline disease severity (IGA), visit, treatment-by-age cohort interaction and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Measured: Baseline, Week 16

  26. Number of Participant Responses With Suspension Acceptability and Palatability Assessment (PK Lead-In) for Participants <10 Years Old at Study Entry

    The questionnaire for Suspension acceptability and palatability assessed the participants ability to swallow the oral suspension product, experience relating to the taste, smell and ease of administering and taking the suspension. The questionnaire contained following Questions: Question 1) How did you (your child) like the taste of the medicine? Question 2) How did you (your child) like the smell of the medicine? Question 3) How easy was it for you (your child) to take the medicine today? Question 4) How easy was it for you to use the oral syringe to give your child the dose today? Responses: Liked Very Much, Liked, Neither Liked nor Disliked, Disliked, Disliked Very Much, Very Easy, Easy, Neither Easy nor Hard, Difficult (or Hard) and Very Difficult (or Hard). The number of participants with these responses are presented. Data is presented as "Question Number-Response-Time point".

    Measured: Week 2

  27. Number of Participant Responses With Tablet Acceptability and Palatability Assessment (PK Lead-In) for Participants >=10 Years Old at Study Entry

    The questionnaire for tablet acceptability and palatability assessed the participants ability to swallow the tablet. The questionnaire contained the question 1) How easy was it for you (your child) to swallow the medicine today? Responses: Very Easy, Easy, Neither Easy nor Hard, Difficult (or Hard) and Very Difficult (or Hard). The number of participants with these responses are presented. Data is presented as "Question Number-Response-Time point".

    Measured: Week 2

  28. Height, Weight and Body Mass Index (BMI) Growth Rate

    Height, Weight and BMI Growth Rate will be reported.

    Measured: 124 Weeks

  29. Change of Immunoglobulin G (IgG) Titers

    Number of participants with change of IgG titers for tetanus vaccine and pneumococcal conjugate will be presented. A primary immune response was assessed in participants who had never received tetanus or pneumococcal conjugate vaccines previously and secondary/booster responses were assessed if the participants had previously received the vaccines. For pneumococcal conjugate vaccine, number of participants with >= 2-fold increase in >=6 pneumococcal serotypes from pre-vaccination timepoint to specified post-vaccination timepoints through the end of the study will be presented. For tetanus vaccine, number of participants with >= 2-fold increase in participants with baseline titer >=0.1 IU/mL from pre-vaccination timepoint to specified post-vaccination timepoints through the end of the study will be presented.

    Measured: Baseline Through End of Study Completion

  30. Pop PK: Maximum Observed Drug Concentration at Steady State (Cmax,ss) of LY3009104

    Pop PK: Cmax,ss was derived by a population pharmacokinetics approach.

    Measured: Predose; 0.25 hours (h); 0.5 h; 1 h; 2-4 h; 4 h and 4-6 h post dose

  31. Pop PK: Area Under the Concentration-Time Curve for Dosing Interval at Steady State (AUCtau,ss) of LY3009104

    Pop PK: AUCtau,ss was derived by a population pharmacokinetics approach.

    Measured: Predose; 0.25 hours (h); 0.5 h; 1 h; 2-4 h; 4 h and 4-6 h post dose

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 May 2019
  2. Study start24 May 2019
  3. Primary completion24 Apr 2022
  4. Study completion22 May 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
516 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03952559
Sponsor's protocol ID
16966
Other IDs
I4V-MC-JAIP, 2018-000349-38, 2018
Acronym
BREEZE-AD-PEDS
Status last verified
Jul 2026
First submitted
15 May 2019
Last updated
5 Aug 2026
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Publications

  • Wollenberg A, Ikeda M, Chu CY, Eichenfield LF, Seyger MMB, Prakash A, Angle R, Zhu D, Pontes M, Paller AS. Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years. J Dermatolog Treat. 2024 Dec;35(1):2411834. doi: 10.1080/09546634.2024.2411834. Epub 2024 Nov 10.

    PubMed 39522957

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in